Skip to content

IDEAYA Biosciences, Inc. IDYA Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$608K

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s capital investments accrued but not yet paid?
IDEAYA Biosciences, Inc. (IDYA) reported capital investments accrued but not yet paid of $1.2M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s capital investments accrued but not yet paid changed year-over-year?
IDEAYA Biosciences, Inc.'s capital investments accrued but not yet paid increased by 83.6% year-over-year, from $654K to $1.2M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s capital investments accrued but not yet paid?
Over 2 years (2022 to 2025), IDEAYA Biosciences, Inc.'s capital investments accrued but not yet paid has grown at a 68.5% compound annual growth rate (CAGR), from $384K to $1.09M.